Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | MMP12 | P39900 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930191 | 0.89 | RXRA (0.54) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL1647807 | 0.86 | MAOA (0.52) | LRRK2TACR2MAOBKDM4EALDH1A1 | |
| SCHEMBL1315281 | 0.83 | ALDH1A1 (0.59) | MAOBKDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL1647426 | 0.82 | LRRK2 (0.62) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL5788379 | 0.81 | NPC1 (0.55) | MMP1TACR2ALDH1A1POLBPPARD | |
| SCHEMBL1648089 | 0.81 | LMNA (0.46) | RXRARXRBRXRGMRGPRX4LRRK2 | |
| SCHEMBL7187849 | 0.81 | MRGPRX4 (0.50) | MRGPRX4LRRK2ALOX5PSEN1ALDH1A1 | |
| SCHEMBL856364 | 0.81 | RXRA (0.59) | RXRARXRBRXRGPTPN1TACR2 | |
| SCHEMBL23496317 | 0.80 | PTPN1 (0.64) | RXRARXRBRXRGPTPN1TACR2 | |
| SCHEMBL30002082 | 0.80 | PTPN1 (0.64) | RXRARXRBRXRGPTPN1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313731-B1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | UCB SA (BE) | 2010-09-29 | — | — | EP | disclosed |
| EP-1313731-B1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | UCB SA (BE) | 2010-09-29 | — | — | EP | disclosed |
| US-6740670-B2 | SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1313731-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002022612-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | CYP3A7, TAS2R7, OXSR1 | RXRA 1171/4885RXRB 1398/4885RXRG 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.